Pluristem Therapeutics Posts Positive Results of Its Cell Therapy
Pluristem Therapeutics Inc. (NASDAQ:PSTI)’s stock price has surged by more than 14% after the company reported positive results of preclinical studies of its PLX-PAD cells in the treatment of Duchenne muscular dystrophy. The Israel based bio-therapeutics company carried out the studies with the Association Duchenne Israel. The results reduced muscle degeneration or injury by approximately 50% as compared to placebo in a mouse model. In a statement, Pluristem’s CEO Zami Aberman said that the company is confident that cell therapy is useful in the treatment of Duchenne muscular dystrophy in human clinical trials.
Jim Simons’ Renaissance Technologies is one of the three hedge funds from our database having stakes in Pluristem Therapeutics Inc. (NASDAQ:PSTI) at the conclusion of the first quarter of 2016.
AMC Adds More IMAX Theaters
IMAX Corporation (USA) (NYSE:IMAX) and AMC Entertainment Holdings Inc (NYSE:AMC) announced to expand their revenue-sharing deal with the addition of 25 IMAX at AMC theatres. The new theatres will be added at new and existing AMC locations, including New York, Los Angeles and Houston. Theaters are expected to be installed from 2016 to 2019. The agreement makes AMC the biggest IMAX exhibitor in North America. As of the end of the first quarter, 15 funds racked by us are bullish on AMC Entertainment Holdings Inc (NYSE:AMC). Israel Englander’s Millennium Management owns 641,695 shares of the company.